

DAFTAR PUSTAKA

- Akbulut, S., Garzali, I. U., Hargura, A. S., Aloun, A., & Yilmaz, S. (2022). Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review. *Journal of gastrointestinal cancer*, 1–12. Advance online publication. <https://doi.org/10.1007/s12029-022-00830-2>.
- An, C., Choi, J.W., Lee, H.S., Lim, H., Ryu, S.J., Chang, J.H., Oh, H.C. (2021). Prediction of the risk of developing hepatocellular carcinoma in health screening examinees: a Korean cohort study. *BMC Cancer*, 21,755.
- Antkowiak, M., Gabr, A., Das, A., Ali, R., Kulik, L., Ganger, D., Moore, C., *et al.* (2019). Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. *Cancers*, 11(6), 879. <https://doi.org/10.3390/cancers11060879>.
- Arima, S., Uto, H., Ibusuki, R., Kumamoto, R., Tanoue, S., Mawatari, S., *et al.* (2014). Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline deficient L-amino acid-defined diet in rats. *Int J Mol Med*, 33, 68-76.
- Asafo-Agyei, K. O., & Samant, H. (2023). *Hepatocellular Carcinoma*. In *StatPearls*. StatPearls Publishing.
- Balogh, J., Victor III, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., & Monsour Jr, H. P. (2016). Hepatocellular carcinoma: a review. *Journal of hepatocellular carcinoma*, 3, 41.
- Bannaga, A., Arasaradnam, R. P. (2020). Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. *World Journal of Gastroenterology*, 26(33), 5022.
- Brookes, M.J., Cooper, B.T. (2007). Hypertension and fatty liver: guilty by association? *J Hum Hypertens*, 21, 264-270.
- Budihusodo, U. Karsinoma Hati. Dalam: Setiati, S., Alwi, I., Sudoyo, A. W., Simadibrata K., M., Setiyohadi, B., Syam A.F. eds. Ilmu Penyakit Dalam Edisi Keenam Jilid I. Jakarta : InternaPublishing, 2014. Pp.3040-3046.
- Calderon-Martinez, E., Landazuri-Navas, S., Vilchez, E., Cantu-Hernandez, R., Mosquera-Moscoso, J., Encalada, S., *et al.* (2023). Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review. *Journal of Clinical Medicine Research*, 15(4), 200–207. <https://doi.org/10.14740/jocmr4902>.

- Caraceni, P., Riggio, O., Angeli, P., Alessandria, C., Neri, S., Foschi, F. G., *et al.* (2018). Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. *Lancet*, 391(10138), 2417–2429.
- Caraceni, P., Tufoni, M., Zaccherini, G., Riggio, O., Angeli, P., Alessandria, C., *et al.* (2021). On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. *Journal of Hepatology*, 74(2), 340–349.
- Carr, B. I., Tumors of the Liver and Biliary Tree. Dalam Longo, D. L., and Fauci, A. S., eds. *Harrison's Gastroenterology and Hepatology*. New York : McGraw-Hill, 2010. Pp.517-525
- Carstensen, B., Read, S.H., Friis, S., Reijo, S., Keskimaki, I., Svensson, A., *et al.* (2016). Cancer incidence in persons with type 1 diabetes: a five country study of 9,000 cancers in type 1 diabetic individuals. *Diabetologia*, 59, 980–988.
- Cassinotto, C., Aubé, C., & Dohan, A. (2017). Diagnosis of hepatocellular carcinoma: an update on international guidelines. *Diagnostic and interventional imaging*, 98(5), 379-391.
- Castro-Narro, G., Moctezuma-Velázquez, C., Male-Velázquez, R., Trejo-Estrada, R., Bosques, F. J., Moreno-Alcántar, R., *et al.* (2022). Position statement on the use of albumin in liver cirrhosis. *Annals of hepatology*, 27(4), 100708, 1-12.
- Charach, L., Zusmanovitch, L., & Charach, G. (2017). Hepatocellular carcinoma. part 2: clinical presentation and diagnosis. *Eur Med J*, 5(1), 81-88.
- Cho, E., Cho, H. A., Jun, C. H., Kim, H. E. E. J., Cho, S. B. U. M., & Choi, S. K. Y. U. (2019). A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. *In Vivo*, 33(5), 1411 LP – 1420. <https://doi.org/10.21873/invivo.11618>
- Cicalese, L. (2022). Hepatocellular Carcinoma (HCC) Clinical Presentation. *Medscape*. <https://emedicine.medscape.com/article/197319-clinical>
- Cunha, G. M., Hosseini, M., Furlan, A., & Fowler, K. J. (2022). Hepatocellular Carcinoma Staging: Differences Between Radiologic and Pathologic Systems and Relevance to Patient Selection and Outcomes in Liver Transplantation. *AJR. American journal of roentgenology*, 218(1), 77–86. <https://doi.org/10.2214/AJR.21.26436>.
- Desen, W. and Japaries, W. *Buku Ajar Onkologi Klinis Edisi 2*. Jakarta: FKUI, 2013.
- Fernandez, J., Claria, J., Amoros, A., Aguilar, F., Castro, M., Casulleras, M., *et al.*

- (2019). Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. *Gastroenterology*, *157*(1), 149–162.
- Fidan, E., Fidan, S., Merev, E., & Kazaz, N. (2022). The Relationship between albumin-Bilirubin grade and survival in hepatocellular carcinoma patients treated with sofosbuvir. *Nigerian journal of clinical practice*, *25*(2), 173–177. https://doi.org/10.4103/njcp.njcp_525_20
- Ghouri, Y. A., Mian, I., & Rowe, J. H. (2017). Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *Journal of carcinogenesis*, *16*.
- Golabi, P., Fazel, S., Otagosuren, M., Sayiner, M., Locklear, C. T., & Younossi, Z. M. (2017). Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. *Medicine*, *96*(9).
- Hansmann, J., Evers, M. J., Bui, J. T., Lokken, R. P., Lipnik, A. J., Gaba, R. C., *et al.* (2017). Albumin-bilirubin and platelet-albumin-bilirubin grades accurately predict overall survival in high-risk patients undergoing conventional transarterial chemoembolization for hepatocellular carcinoma. *J Vasc Interv Radiol*, *28*(9), 1224-1231.e2. doi:10.1016/j.jvir.2017.05.020.
- Hassanipour, S., Vali, M., Gaffari-Fam, S., Nikbakht, H. A., Abdzadeh, E., Joukar, F., Pourshams, A., *et al.* (2020). The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. *EXCLI journal*, *19*, 108
- Hay, N. (2016). Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? *Nat Rev Cancer*, *16*, 635–49.
- Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., *et al.* (2018). AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology (Baltimore, Md.)*, *67*(1), 358–380. <https://doi.org/10.1002/hep.29086>.
- Hiraoka, A., Kumada, T., Kudo, M., Hirooka, M., Tsuji, K., Itobayashi, E., *et al.* (2017). Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics). Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. *Liver Cancer*, *6*, 204-215.
- Hsu, W. F., Hsu, S. C., Chen, T. H., Lin, C. H., Lin, Y.C., Chang, Y. W. Wang, *et al.* (2022). Modified Albumin–Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy. *Cancers*, *14*(5083), 1-13.

- Indonesian Liver Cancer Study Group. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta: Perhimpunan Peneliti Hati Indonesia, 2017.
- Kasmari, A.J., Welch, A., Liu, G., Leslie, D., McGarrity, T., Riley, T. (2017). Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome. *Am J Med*, 130, 746.e1-7.
- Kerdsuknirun, J., Vilaichone, V., Vilaichone, R.K. (2018). Clinical outcome and predictive factors of variceal bleeding in patients with hepatocellular carcinoma in Thailand. *Asian Pac. J. Cancer Prev*, 19, 3301–3305.
- Kim, H. D., Bang, Y., Lee, M. A., Kim, J. W., Kim, J. H., Chon, H. J., *et al.* (2020). Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. *Liver international : official journal of the International Association for the Study of the Liver*, 40(10), 2544–2552. <https://doi.org/10.1111/liv.14573>.
- Kong, J. Y., Li, S. M., Fan, H. Y., Zhang, L., Zhao, H. J., Li, S. M. (2018). Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. *Medicine*, 97(33), 1-8. <https://doi.org/10.1097/MD.00000000000011872>
- Lee, J. J. B., Park, J. S., Hong, H. P., Kim, M. S., Koo, D. H., Lee, H., Nam, H. (2013). Evaluation of Pretreatment Albumin–Bilirubin Grade as a Better Prognostic Factor Compared to Child–Pugh Classification in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization Combined with Radiotherapy. *Journal of Personalized Medicine*, 13(354), 1-11.
- Lee, S. K., Song, M. J., Kim, S. H. & Park, M. (2019). Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. *PloS one*, 14(5), pp.1-19.
- Li, X., Wang, X., & Gao, P. (2017). Diabetes Mellitus and Risk of Hepatocellular Carcinoma. *BioMed Research International*, 2017, 5202684. <https://doi.org/10.1155/2017/5202684>
- Lopez-Lopez, V., Gomez-Ruiz, A., Lopez-Conesa, A., Brusadin, R., Cayuela, V., Caballero-Illanes, A., *et al.* (2020) Effects of primary hypertension treatment in the oncological outcomes of hepatocellular carcinoma. *Ann Transl Med*, 8(14):844. doi: 10.21037/atm.2020.04.40.
- Maharani, G. A., Nugraha, E. S., & Sugianli, A. K. (2021). Clinical Manifestations and Laboratory Examination Findings of Hepatocellular Carcinoma at a

- Tertiary Care Facility in Bandung: An Annual Observation Study. *Althea Medical Journal*, 8(3), 132-137.
- Maimunah, U., Restu, A. P., Nusi, I. A., Purbayu, H., Sugihartono, T., Kholili, U., *et al.* (2020). Albumin-Bilirubin Grade as a Three-Month Survival Predictor in Hepatocellular Carcinoma Patients After Initial Transarterial Chemoembolization (ALBI Grade Predicting Survival in HCC Treated with TACE). *Systematic Reviews in Pharmacy*, 11(5).
- Malaguarnera, R., Belfiore, A. (2014). The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. *Front Endocrinol (Lausanne)*, 5(10).
- Mansour, D., Masson, S., Hammond, J., Leithead, J. A., Johnson, J., Rahim, M. N., *et al.* (2023). British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis - part 3: special circumstances. *Frontline gastroenterology*, 14(6), 474–482. <https://doi.org/10.1136/flgastro-2023-102432>.
- Michelotti, G.A., Machado, M.V., Diehl, A.M. (2013). NAFLD, NASH and liver cancer. *Nat Rev Gastroenterol Hepatol*, 10, 656–665.
- Mu, X. M., Wang, W., Jiang, Y. Y., & Feng, J. (2020). Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. *International Journal of Environmental Research and Public Health*, 17(9), 3108. <https://doi.org/10.3390/ijerph17093108>.
- Nguyen, T. T. H., Nguyen, V. H., Nguyen, V. H., Nguyen, T. L., Le, V. Q. (2019). Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam. *Cancer Control*, 26(1). doi:10.1177/1073274819865269.
- Núñez, K. G., Sandow, T., Patel, J., Hibino, M., Fort, D., Cohen, A.J., Thevenot, P. (2022). Hypoalbuminemia is a Hepatocellular Carcinoma Independent Risk Factor for Tumor Progression in Low-Risk Bridge to Transplant Candidates. *Cancers*, 14(1684), 1-17.
- Osaki, Y., Taniguchi, S., Tahara, A., Okamoto, M., Kishimoto, T. (2012). Metabolic syndrome and incidence of liver and breast cancers in Japan. *Cancer Epidemiol*, 36, 141–147.
- Patel, A. D., (2020). Hepatocellular Carcinoma Staging. Medscape. <https://emedicine.medscape.com/article/2007061-overview>.
- Puri, D. A., Murti, S., & Riastiti, Y. (2021). Insidensi dan Karakteristik Karsinoma Hepatoseluler di RSUD Abdul Wahab Sjahranie Samarinda: Incidence and Characteristics of Hepatocellular Carcinomas in RSUD Abdul Wahab

- Sjahanie Samarinda. *Jurnal Sains dan Kesehatan*, 3(2), 158-164.
- Sakamaki, A., Takamura, M., Sakai, N., Watanabe, Y., Arao, Y., Kimura, N., *et al.* (2022) Longitudinal increase in albumin–bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis. *PLoS ONE*, 17(2), e0263464. <https://doi.org/10.1371/journal.pone.0263464>.
- Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., *et al.* (2012). Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. *Hepatology*, 56, 1004–1014.
- Shawon, MA-A., Yousuf, M.A.K., Raheem, E., Ahmed, S., Dipti, T.T., Hoque, M.R., *et al.* (2020). Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh. *PLoS ONE*, 15(4), e0232121.
- Sinn, D.H., Lee, H.W., Paik, Y.H., Kim, Y.J., Kim, K.M., Kim, J.H., *et al.* (2021). Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study. *Digestive Diseases and Sciences*, 66, 315–324.
- Soeters, P.B., Wolfe, R.R., Shenkin, A. (2019). Hypoalbuminemia: Pathogenesis and Clinical Significance. *JPEN Journal Parenteral and Enteral Nutrition*, 43, 181–193.
- Solà, E., Solé, C., Simón-Talero, M., Martín-Llahí, M., Castellote, J., Garcia-Martínez, R., *et al.* (2018). Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. *Journal of Hepatology*, 69, 1250-1259.
- Song, Y., Yang, H., Lin, L., Jiang, K., Liu, W. T., Wang, B. M., Lin, R. (2019). Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = *Chinese journal of hepatology*, 27(10), 772–776. <https://doi.org/10.3760/cma.j.issn.1007-3418.2019.10.007>
- Suresh, D., Srinivas, A. N., & Kumar, D. P. (2020). Etiology of hepatocellular carcinoma: special focus on fatty liver disease. *Frontiers in Oncology*, 10, 601710.
- Tada, T., Kumada, T., Hiraoka, A., Atsukawa, M., Hirooka, M., Tsuji, K., *et al.* (2021). Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. *Scientific reports*, 11(1), 14474. <https://doi.org/10.1038/s41598-021-93794-5>

- Tada, T., Kumada, T., Toyoda, H., Tsuji, K., Hiraoka, A., Michitaka, K., *et al.* (2018). Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. *Journal of gastroenterology and hepatology*, *34*(6), 1066–1073. <https://doi.org/10.1111/jgh.14564>.
- Tsoris, A., Marlar, C.A. Use of The Child Pugh Score In Liver Disease. [Updated 2023 Mar 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542308/>
- Tunissiolli, N. M., Castanhole-Nunes, M. M. U., Biselli-Chicote, P. M., Pavarino, É. C., da Silva, R. F., & Goloni-Bertollo, E. M. (2017). Hepatocellular carcinoma: a comprehensive review of biomarkers, clinical aspects, and therapy. *Asian Pacific journal of cancer prevention: APJCP*, *18*(4), 863.
- Wang, R., Liu, Y., Sun, H., Wang, T., Li, C., Fan, J., & Wang, Z. (2021). Estradiol is significantly associated with prognosis in non-surgical liver cancer patients: from bench to bedside. *Aging*, *13*(3), 3483–3500. <https://doi.org/10.18632/aging.202280>.
- Wangensteen, K. J., & Chang, K.-M. (2021). Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. *Hepatology*, *73*(S1), 27–37. <https://doi.org/https://doi.org/10.1002/hep.31481>.
- Wong, L. L., Lee, L. Y., Karasaki, K., Ogihara, M., & Tran, C. (2022). Management of hepatocellular carcinoma in patients who are 70 years or older. *Surgery Open Science*, *10*, 53–58. <https://doi.org/https://doi.org/10.1016/j.sopen.2022.07.003>.
- Wu, E. M., Wong, L. L., Hernandez, B. Y., Ji, J.-F., Jia, W., Kwee, S. A., & Kalathil, S. (2018). Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. *Hepatoma Research*, *4*. <https://doi.org/10.20517/2394-5079.2018.87>
- Xu, H., Wei, Y., Zhang, Y., Xu, Y., Li, F., Liu, J., Zhang, W., Han, X., Tan, R., & Shen, P. (2012). Oestrogen attenuates tumour progression in hepatocellular carcinoma. *The Journal of pathology*, *228*(2), 216–229. <https://doi.org/10.1002/path.4009>.
- Xu, Y. X., Wang, Y. B., Tan, Y. L., Xi, C., Xu, X. Z. (2019). Prognostic value of pretreatment albumin to bilirubin ratio in patients with hepatocellular cancer: A meta-analysis. *Medicine*, *98*(2).
- Yan, H., Wang, X., Liu, X., Wang, P., Yu, L., Zhou, D., & Yang, Z. (2022). The

- survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma: basing on competing risk model. *BMC cancer*, 22(1), 185. <https://doi.org/10.1186/s12885-022-09293-x>.
- Yang, Y., Zhang, B.H., Gong, J.P. (2018). Genes and molecular mechanisms affecting the correlation between liver cancer and diabetes mellitus. *Zhonghua gan zang bing za zhi Chin. J. Hepatol*, 26, 718–720.
- Yeh, H., Chiang, C.-C., & Yen, T.-H. (2021). Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. *World Journal of Gastroenterology*, 27(26), 4104–4142. <https://doi.org/10.3748/wjg.v27.i26.4104>.
- Yeh, S. H., & Chen, P. J. (2010). Gender disparity of hepatocellular carcinoma: the roles of sex hormones. *Oncology*, 78(Suppl 1), 172–179.
- Yim, W. W., Kwan, S. W., Johnson, G., & Yetisgen, M. (2017). Classification of hepatocellular carcinoma stages from free-text clinical and radiology reports. In *AMIA annual symposium proceedings* (Vol. 2017, p. 1858). American Medical Informatics Association.
- Zhou, J., Sun, H., Wang, Z., Cong, W., Wang, J., Zeng, M., *et al.* (2020). Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). *Liver Cancer*, 9(6), 682-720.



UNIVERSITAS
GADJAH MADA

Skor Albumin Bilirubin (ALBI) Sebagai Prediktor Survival 1 Tahun Pasien Dengan Karsinoma Hepatoseluler Di RSUP Dr Sardjito
Tri Indriaswati, DR.dr.Neneng Ratnasari, SpPD-KGEH, FINASIM; dr.Sutanto Maduseno, SpPD-KGEH
Universitas Gadjah Mada, 2024 | Diunduh dari <http://etd.repository.ugm.ac.id/>